摘要:

Microsomal cytochromes and some oxidative activities were determined in normal rat liver, tumour-bearing rat liver and Morris hepatoma 3924-A. Except for a moderate lowering of cytochromes and enzymes in host livers, the relation between TPNH-cytochrome c reductase activity and cytochrome P-450 TPNH reduction, both increased by phenobarbital (PB) and decreased by 3-methylcolanthrene (3-MC) treatment, is noteworthy. In tumour cytochromes b5 and P-450 are absent and TPNH-cytochrome c reductase is unmeasurable and not induced by PB or 3-MC treatment. Aminopyrine demethylase activity, instead, is comparable with normal or host liver and it is modified by PB or 3-MC treatment in the same way, despite the microsomal enzymes pathway disorganization. Microsomal enzymatic defect selectivity in tumours may be due to a deranged microsome-linked growth control.

ISSN:0030-2414    

DOI:10.1159/000225308

出版商:S. Karger AG    

年代:1979

数据来源: Karger

摘要:

ACNU was highly effective for Sato lung carcinoma transplanted intravenously or intramuscularly by using a large single dose, and the cytotoxic action of ACNU for SLC showed clear dependence upon tumor size. Nonspecific activation of host-defence mechanism by Propionibacteriumacnes contributed to the suppression for the regrowth of solid SLC treated by ACNU.

ISSN:0030-2414    

DOI:10.1159/000225309

出版商:S. Karger AG    

年代:1979

数据来源: Karger

摘要:

Serum lipids were determined in patients with hepatoma, liver cirrhosis and healthy controls. Serum total cholesterol, esterified cholesterol, triglycerides, and phospholipid were increased in cases with hepatoma compared to those with cirrhosis, irrespective of a history of liver cirrhosis in the hepatome group of patients. From this study one can conclude that the determination of serum lipids is useful in differentiating carcinoma from liver cirrhosis. This may be used as a tool for the early detection of hepatoma complicating liver cirrhosis.

ISSN:0030-2414    

DOI:10.1159/000225310

出版商:S. Karger AG    

年代:1979

数据来源: Karger

摘要:

Serum lysozyme has been demonstrated to be an indicator for macrophage activity in the tumor-bearing host. Therefore, we investigated lysozyme levels in the sera of 336 untreated tumor patients (121 malignant melanoma, 61 lung cancers, 70 cervical cancers, 49 breast cancers and 35 benign breast tumors, and 36 healthy controls). Patients with malignant melanoma and lung cancer had significantly higher lysozyme levels than the healthy controls. Within the clinical stages in melanoma, there was a decrease of lysozyme in stages II and III in comparison to stage I, but still above that of the control values. Patients with benign breast tumors had normal levels, whereas in breast cancer patients of stages I and II there was a significant reduction in the lysozyme levels. In stages III and IV no differences to the control group could be detected. In patients with cervical cancer (FIGO II and III) serum lysozyme levels were found to be within the normal range. From this study it can not be concluded that serum lysozyme reflects the immunological reactivity of the tumor bearer. Nevertheless, the reduced levels in stages I and II of breast cancer might point to an immunological defect.

ISSN:0030-2414    

DOI:10.1159/000225311

出版商:S. Karger AG    

年代:1979

数据来源: Karger

摘要:

A case of C cell thyroid adenoma in a 47-year-old female patient is described. The nodule showed progression over 34 years. The adenoma cells showed histochemical and ultrastructural properties characteristic for C cells. Histologic examination revealed no atypical features of nodule cells nor infiltration of capsule by neoplastic cells. In the period of 8 years following the excision there was neither recurrence nor metastases.

ISSN:0030-2414    

DOI:10.1159/000225312

出版商:S. Karger AG    

年代:1979

数据来源: Karger

摘要:

Various immunological parameters were evaluated in untreated Hodgkin’s patients before and after sensitization with dinitrochlorobenzene (DNCB). The ratio (r) of these parameters after/before DNCB sensitization for patients and second/first samples in the controls were calculated. There were significantly more patients in the r > 1.1 group for PHA and Con A responses and for peripheral blood T cell percentages. These data suggest that DNCB sensitization may have a nonspecific immunopotentiation effec

ISSN:0030-2414    

DOI:10.1159/000225313

出版商:S. Karger AG    

年代:1979

数据来源: Karger

摘要:

Between the period of 1956 and 1973, 271 radical and semiradical neck dissections were performed. The ‘en bloc’ method was used in 75 patients with cancer of the larynx and in 47 thyroid cancer patients. Analysis of the patient material revealed the operative mortality of 1.5%. 5-year survival was observed in 34.8% of the patients. The incidence of local recurrence amounted to

ISSN:0030-2414    

DOI:10.1159/000225314

出版商:S. Karger AG    

年代:1979

数据来源: Karger

摘要:

Some of the human prostatic cells in culture apparently produce oncornavirus-like particles. Bromodeoxyuridine does not enhance the production of these particles. On the contrary, this drug depresses such production. This depression is likely to be due to the cytotoxic effects of bromodeoxyuridine for these cells. These results can be interpreted to suggest that the human prostatic cells used in this study do not contain endogenous oncornavirus genetic information that is inducible. Purified human interferon inhibits the production of oncornavirus-like particles by these prostatic cells. It also inhibits the rate of cellular DNA synthesis in these cells. These results are consistent with the notion that the inhibitory effects of interferon are mediated through its effect on cellular biosynthetic machinery.

ISSN:0030-2414    

DOI:10.1159/000225315

出版商:S. Karger AG    

年代:1979

数据来源: Karger

摘要:

This paper reviews a series of sequential clinical trials at the University of Arizona Cancer Center which were designed to improve the outcome in both advanced and early breast cancer by utilizing the combination of intravenous adriamycin and oral cyclophosphamide (A-C) alone or with the addition of other agents or modalities. Our initial trial in advanced breast cancer with A-C produced an overall objective response rate of 78 % in 51 patients with advanced breast cancer without prior chemotherapy. The median duration of disease control was 12 months. Subsequent studies showed that the addition of either vincristine or the androgen, calusterone, effectively doubled the remission duration and prolonged survival. However, we learned that lower doses of adriamycin reduced the efficacy of the A-C combination (response rate 53%) although it permitted a longer duration of drug administration before reaching potentially cardiotoxic limits. Our surgical adjuvant trial with 6 months of treatment with A-C was begun in 1974. There has been only a 9% relapse rate in stage II patients thus far, with a median follow-up of close to 2 years. A subset of stage II patients who received regional radiotherapy along with A-C have not yet shown added benefit compared to the use of A-C alone. Since 1975, stage I patients have been treated with an abbreviated treatment schedule (3 courses of A-C over 9 weeks). While there have not yet been relapses in this category, much longer periods of follow-up will be required. The use of A-C (plus other drugs) has clearly provided excellent palliation and improved survival in patients with advanced or recurrent breast cancer; in our opinion it should be used as initial cytotoxic chemotherapy. The brief intensive program of A-C as a surgical adjuvant also shows considerable promise for erradicating occult micrometastases in both pre- and postmenopausal women.

ISSN:0030-2414    

DOI:10.1159/000225316

出版商:S. Karger AG    

年代:1979

数据来源: Karger

ISSN:0030-2414    

DOI:10.1159/000225317

出版商:S. Karger AG    

年代:1979

数据来源: Karger